Sugi Predict

Sugi Predict / Compounds / SCHEMBL995357

SCHEMBL995357

SCHEMBL995357

CCO/C=C(\C(=O)OCC)C(=O)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.58
▸ MAPT P10636 4/20 0.58
▸ MEN1 O00255 5/20 0.57
▸ KMT2A Q03164 5/20 0.57
▸ GAA P10253 2/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ KDM4E B2RXH2 2/20 0.47
▸ HSP90AA1 P07900 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ DHODH Q02127 2/20 0.46
▸ LMNA P02545 2/20 0.46
▸ PLIN1 O60240 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ PLIN5 Q00G26 1/20 0.46
▸ ABHD5 Q8WTS1 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ CNR2 P34972 2/20 0.44
▸ NR1H4 Q96RI1 1/20 0.44
▸ CES2 O00748 1/20 0.43
▸ CES1 P23141 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5263495 1.00 ALDH1A1 (0.58) ALDH1A1MAPTMEN1KMT2AGAA
SCHEMBL995358 1.00 ALDH1A1 (0.58) ALDH1A1MAPTMEN1KMT2AGAA
SCHEMBL5286421 0.88 DHODH (0.51) ALDH1A1MAPTMEN1KMT2AGAA
SCHEMBL5286417 0.88 DHODH (0.51) ALDH1A1MAPTMEN1KMT2AGAA
SCHEMBL14581582 0.88 DHODH (0.51) ALDH1A1MAPTMEN1KMT2AGAA
SCHEMBL2901221 0.85 CES2 (0.47) ALDH1A1MAPTMEN1KMT2AGAA
SCHEMBL16050362 0.85 MAPT (0.63) ALDH1A1MAPTMEN1KMT2AGAA
SCHEMBL2901225 0.85 CES2 (0.47) ALDH1A1MAPTMEN1KMT2AGAA
SCHEMBL9280536 0.85 MAPT (0.63) ALDH1A1MAPTMEN1KMT2AGAA
SCHEMBL10359660 0.84 CES2 (0.50) ALDH1A1MAPTMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376076-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) DANA-FARBER CANCER INSTITUTE, INC. 2024-11-14 — — US disclosed
CN-118401507-A Inhibitors targeting ubiquitin-specific protease 7 (USP 7) 丹娜法伯癌症研究院 2024-07-26 — — CN disclosed
EP-4373816-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) Dana-Farber Cancer Institute, Inc. (US) 2024-05-29 — — EP disclosed
WO-2023003973-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-01-26 — — WO disclosed
US-8067447-B2 Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2011-11-29 — — US disclosed
US-8008306-B2 Quinoline compounds KOWA COMPANY, LTD. (JP) 2011-08-30 — — US disclosed
EP-2284157-A1 Quinolines useful in treating cardiovascular disease Wyeth (US) 2011-02-16 — — EP disclosed
EP-2272843-A1 QUINOLINE COMPOUND Kowa Company, Ltd. (JP) 2011-01-12 — — EP disclosed
CN-101878031-A The inhibitors of kinases that is used for the treatment of myeloproliferative disease and other proliferative diseases DECIPHERA PHARMACEUTICALS LLC 2010-11-03 — — CN disclosed
US-20100076014-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY 2010-03-25 — — US disclosed
US-4980353-A BACTERICIDES, ANIMAL GROWTH REGULATORS BAYER AKTIENGESELLSCHAFT (DE) 1990-12-25 — — US disclosed
US-4977263-A USING CHEMICAL INTERMEDIATES BAYER AKTIENGESELLSCHAFT (DE) 1990-12-11 — — US disclosed
US-4958045-A ENAMINES, BACTERICIDES, ANIMAL GROWTH REGULATORS BAYER AKTIENGESELLSCHAFT (DE) 1990-09-18 — — US disclosed
US-4902795-A Intermediates for 1,8-bridged 4-quinolone-3-carboxylic acid antibacterials BAYER AKTIENGESELLSCHAFT (DE) 1990-02-20 — — US disclosed
US-4859773-A Preparation of 1,8-bridged 4-quinoline-3-carboxylic acids BAYER AKTIENGESELLSCHAFT (DE) 1989-08-22 — — US disclosed
US-4841059-A CHEMICAL INTERMEDIATES FOR BACTERICIDES BAYER AKTIENGESELLSCHAFT (DE) 1989-06-20 — — US disclosed
US-4762831-A PROMOTE ANIMAL GROWTH BAYER AKTIENGESELLSCHAFT (DE) 1988-08-09 — — US disclosed
US-4725595-A 1,8-bridged 4-quinolone-3-carboxylic acid antibacterials BAYER AKTIENGESELLSCHAFT (DE) 1988-02-16 — — US disclosed
US-4599334-A 7-(3-aryl-1-piperazinyl)- and 7-(3-cyclohexyl-1-piperazinyl)-3-quinolonecarboxylic acid antibacterials BAYER AKTIENGESELLSCHAFT (DE) 1986-07-08 — — US disclosed
US-4588726-A 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(3-oxo-1-piperazinyl)-3-quinolinecarboxylic acid antibacterial agents BAYER AKTIENGESELLSCHAFT (DE) 1986-05-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376076-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) USP7, USP47, USP2 ALDH1A1 2692/4885MAPT 1018/4885MEN1 3697/4885
US-20100076014-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF NFRKB, NFKBIA, NFKB1 ALDH1A1 3430/4885MAPT 3994/4885MEN1 3710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.